Metformin acts on miR-181a-5p/PAI-1 axis in stem cells providing new strategies for improving age-related osteogenic differentiation decline
Stem Cells · 2024
DOI: 10.1093/stmcls/sxae057 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cells, 2024. Verfasst von Guanhao Hong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cell Research and Cellular Therapy Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, People's Republic o…. Hauptthemen laut MEDLINE: MicroRNAs, Osteogenesis, Cell Differentiation, Metformin. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: Science and Technology Program of Zhanjiang, Medical Scientific Research Foundation of Guangdong Province.
Abstract (Originalsprache)
A general decline in the osteogenic differentiation capacity of human bone marrow mesenchymal stem cells (hBMSCs) in the elderly is a clinical consensus, with diverse opinions on the mechanisms. Many studies have demonstrated that metformin (MF) significantly protects against osteoporosis and reduces fracture risk. However, the exact mechanism of this effect remains unclear. In this study, we found that the decreased miR-181a-5p expression triggered by MF treatment plays a critical role in recovering the osteogenic ability of aging hBMSCs (derived from elderly individuals). Notably, the miR-181a-5p expression in hBMSCs was significantly decreased with prolonged MF (1000 μM) treatment. Further investigation revealed that miR-181a-5p overexpression markedly impairs the osteogenic ability of hBMSCs, while miR-181a-5p inhibition reveals the opposite result. We also found that miR-181a-5p could suppress the protein translation process of plasminogen activator inhibitor-1 (PAI-1), as evidenced by luciferase assays and Western blots. Additionally, low PAI-1 levels were associated with diminished osteogenic ability, whereas high levels promoted it. These findings were further validated in human umbilical cord mesenchymal stem cells (hUCMSCs). Finally, our in vivo experiment with a bone defects rat model confirmed that the agomiR-181a-5p (long-lasting miR-181a-5p mimic) undermined bone defects recovery, while the antagomiR-181a-5p (long-lasting miR-181a-5p inhibitor) significantly promoted the bone defects recovery. In conclusion, we found that MF promotes bone tissue regeneration through the miR-181a-5p/PAI-1 axis by affecting MSC osteogenic ability, providing new strategies for the treatment of age-related bone regeneration disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stem Cell Research and Cellular Therapy Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, People's Republic of China.
- Reproductive Medicine Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, People's Republic of China.
- Orthopedic Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, People's Republic of China.
ORCID-Profile: Jiafeng Wang
Förderung
- Science and Technology Program of Zhanjiang
- Medical Scientific Research Foundation of Guangdong Province
Zitieren
APA
Hong, G., Zhou, Y., Yang, S., Yan, S., Lu, J., Xu, B., Zhan, Z., Jiang, H., Wei, B., & Wang, J. (2024). Metformin acts on miR-181a-5p/PAI-1 axis in stem cells providing new strategies for improving age-related osteogenic differentiation decline. Stem Cells. https://doi.org/10.1093/stmcls/sxae057
Vancouver
Hong G, Zhou Y, Yang S, Yan S, Lu J, Xu B, et al. Metformin acts on miR-181a-5p/PAI-1 axis in stem cells providing new strategies for improving age-related osteogenic differentiation decline. Stem Cells. 2024. doi:10.1093/stmcls/sxae057
BibTeX
@article{Hong2024,
author = {Hong, Guanhao and Zhou, Yulan and Yang, Shukai and Yan, Shouquan and Lu, Jiaxu and Xu, Bo and Zhan, Zeyu and Jiang, Huasheng and Wei, Bo and Wang, Jiafeng},
title = {Metformin acts on miR-181a-5p/PAI-1 axis in stem cells providing new strategies for improving age-related osteogenic differentiation decline},
journal = {Stem Cells},
year = {2024},
doi = {10.1093/stmcls/sxae057}
}
EUVIMED